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Abstract
Background: NS2359 is a potent reuptake blocker of noradrenalin, dopamine, and serotonin. The
aim of the study was to investigate the efficacy, safety and cognitive function of NS2359 in adults
with a DSM IV diagnosis of ADHD.
Methods: The study was a multi-centre, double-blind, randomized placebo-controlled, parallel
group design in outpatient adults (18–55 years) testing 0.5 mg NS2359 vs. placebo for 8 weeks.
Multiple assessments including computerized neuropsychological evaluation were performed.
Results: There was no significant difference between NS2359 (n = 63) versus placebo (n = 63) on
the primary outcome measure reduction in investigator rated ADHD-RS total score (7.8 versus
6.4; p < 0.45). However, in subjects with the inattentive subtype, there were significantly more
responders in the NS2359 group compared to placebo (41% versus 7%; p < 0.01). For all secondary
variables (ADHD-RS patient rated; The Conners Adult ADHD Scale; The Brown Adult Scale, and
CGI-improvement scale) there were no significant differences between the two groups; however,
in the inattentive subgroup, the response to treatment was significantly larger than to placebo.
NS2359 improved composite factor scores of attention, episodic- and working memory. No
serious adverse events were reported with insomnia, headaches and loss of appetite most
commonly reported as side effects.
Conclusion: No overall effect of NS2359 was found on overall symptoms of ADHD. There was
also a modest signal of improvement in the inattentive adults with ADHD and cognition warranting
further exploration using differing doses.
Background
Attention deficit-hyperactivity disorder (ADHD) is an
increasingly recognized and heterogeneous disorder of
unclear etiology [1] characterized by core symptoms of
hyperactivity, inattentiveness, and impulsivity. The preva-
lence of ADHD in school-age children is estimated at 6–
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8% worldwide [2], with symptoms persisting into adult-
hood in approximately 50% of individuals with child-
hood onset ADHD [3]. Recent epidemiological data
suggest that ADHD occurs in 4.4% of adults in the US [4].
ADHD in adults is associated with academic, employ-
ment, and marital difficulties, as well as comorbid psychi-
atric disorders such as substance abuse, depression,
anxiety, and personality disorders [5-7]. Moreover, cost-
of-illness data in untreated adults without ADHD show
significantly higher cost than in matched adults with
ADHD both for medical and societal expenses [8].
The aggregate data also support the concept that ADHD in
adults shares many phenotypic and genotypic similarities
with the childhood form of the disorder [9]. Due to the
phenotypic, genotypic, and pharmacological response
similarities between adults and children with ADHD [9]
the ethical considerations of exposing children to novel
compounds with potential adverse events have led to
adults with ADHD being used increasingly for early phase
II trials.
Currently, the treatment of ADHD in adults is largely
predicated upon use of both stimulant and non-stimulant
medications, as well as adjunctive structured psychother-
apies [10]. Despite the availability of both FDA-approved
and other agents for ADHD, a number of individuals
either cannot tolerate, or do not respond to existing com-
pounds necessitating the development of alternative
agents.
While the precise etiology of ADHD is unknown contin-
ued interest has been focused on the role of the catecho-
laminergic and nicotinic/cholinergic systems in ADHD.
Evidence that dopamine dysfunction plays a role in
ADHD comes from findings from studies describing
excessive motor activity and cognitive dysfunction and
neuroanatomical studies. For instance, compared to con-
trols, differences have been identified in the binding
potential of the dopamine transporter protein in adults
with ADHD [11-13]. Similarly, candidate genes and func-
tional imaging abnormalities in ADHD point to altera-
tions in areas of the brain rich in dopaminergic/
noradrenergic innervations. Along with longstanding
associations of cigarette smoking in ADHD [14,15], recent
work has shown the efficacy of nicotine and nicotinic ana-
logs in the treatment of ADHD [16,17]. Along those lines,
predominately dopaminergic, noradrenergic, and mixed
dopaminergic/noradrenergic agents have been shown to
have efficacy in treating ADHD [18,19].
One such mixed monoamine reuptake blocker is the
novel agent NS2359, which acts by equipotent reuptake
blockade across the noradrenalin, dopamine and serot-
onin transporters. NS2359 has also been shown to
enhance the release of acetylcholine in the frontal cortex
and hippocampus an effect considered relevant for atten-
tional performance [20,21]. In a previous study NS2359
was found to have positive effects on attention and mem-
ory in healthy volunteers [22] and given the high degrees
of cognitive dysfunction in ADHD [23], these effects taken
together with the mode of action of NS2359 makes it a
suitable candidate for treating ADHD. Moreover, the slow
entrance of NS2359 into the human brain makes it a can-
didate for the treatment of ADHD with minimal potential
for abuse.
In this paper we report the results of a randomized, dou-
ble blind, placebo-controlled study of NS2359 in the
treatment of adults with ADHD. The primary aim of the
study was to investigate the efficacy and safety of NS2359
in DSM IV diagnosed adults with ADHD. The secondary
aim was to evaluate the effects of NS2359 on cognitive
function, particularly attention, working memory and epi-
sodic memory. This study was designed as an exploratory,
signal-detection, Phase IIa study to provide proof-of-con-
cept for this novel compound prior to embarking on a
larger scale Phase IIb program.
Methods
2.1 Subjects
Patients were recruited by advertisements in local media.
Three sites in the US participated in the trial. The study
was conducted according to the Declaration of Helsinki
and was approved by independent ethics committee or
institutional review board at each site. All subjects pre-
sented written informed consent. Adult outpatients of
either sex (aged 18–55 inclusive) who met DSM-IV criteria
for Attention Deficit Hyperactivity Disorder [24] were
entered into the study. ADHD needed to be manifested in
clinical evaluation and confirmed by structured interview
using the Kiddie-Schedule for Affective Disorders (K-
SADS-E) adult ADHD module. All subtypes of ADHD
were allowed to enroll in the study. Patients were also
required to have a CGI Global Severity (GS) score ≥ 4
indicative of moderate impairment. Patients were
excluded if they had any clinically unstable medical con-
dition, clinically significant abnormal baseline laboratory
values, mental retardation, psychotic disorder, bipolar
disorder, current depression (HAM-D > 15), eating disor-
der, or organic brain disorders including non-febrile sei-
zure disorder. Patients currently (within the past 6
months) known to abuse or to be dependent on any drug,
including alcohol or a positive urine drug screen for
cocaine, heroin, or marijuana were excluded. Patients
were not allowed to use any concurrent medication for the
treatment of ADHD. Prohibited treatments were stimu-
lants within 1 week prior to randomization, benzodi-
azepines, anticonvulsants and lithium for 2 weeks,
tricyclic, atypical, and selective serotonin reuptake inhibi-Behavioral and Brain Functions 2008, 4:24 http://www.behavioralandbrainfunctions.com/content/4/1/24
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tor antidepressants within 4 weeks and antipsychotics and
monoamine oxidase inhibitors for 8 weeks. Qualified
were randomized to receive 0.5 mg NS2359 or placebo
orally in the morning for eight weeks without dietary
restrictions, and then followed off drug for an additional
4 weeks. The drug was provided as tablets of 0.25 mg or
corresponding placebo tablets.
2.2 Assessments
The primary efficacy endpoint was the ADHD-rating scale
(investigator-rated) which was administered at all study
visits. Additional symptom rating scales were used to
assess efficacy of secondary endpoints: the ADHD-RS
(self-rating scale), the Clinical Global Impression (CGI),
the Conners (CAARS) Adult ADHD Scale (self-rating
scale) and the Brown Adult Scale (self-rating scale), the
latter addressing issues of time management, organiza-
tion, hierarchical thinking etc. in multiple clinical
domains [25].
Additional rating scales were used to evaluate co-occur-
ring mood and anxiety. The Hamilton Depression Scale
(HAM-D) was completed by the physician at screening
(patients being excluded if the score exceeded 15), base-
line (week 0) and at the end of treatment (week 8). The
Hamilton Anxiety Scale was also completed by the physi-
cian at baseline (week 0) and at the end of treatment
(week 8).
The Cognitive Drug Research (CDR) computerized assess-
ment system was used to assess cognitive function in this
study. The system has been widely used in clinical
research [26,27] and was used previously to identify the
positive effects of with NS 2359 on attention and memory
in healthy volunteers [22]. The system is a notebook PC
based set of tests of attention, working memory and epi-
sodic memory. The information is presented on the com-
puter screen and the patient responds on all tasks using a
response module containing two buttons, one marked
'NO' and the other 'YES'. The System has numerous paral-
lel forms to allow for repeated testing over hours, weeks or
months. The instructions are read to the patient for each
task, and the test administrator then initiates each task
and monitors the performance of the patient to ensure
compliance with the instructions. The data are captured
automatically by the computer. The CDR tests selected for
this study comprised three attention tests: simple reaction
time, digit vigilance and choice reaction time; two work-
ing memory tasks: Spatial Working Memory and Numeric
Working Memory; and three episodic memory tasks:
immediate and delayed word recognition and picture rec-
ognition. Each of the tasks is brief, lasting 1–2 minutes,
and each test session took about 18 minutes for the
patient to complete. The tests have been described in
detail previously [26,27]. To familiarize the patients with
the tests and overcome training effects, each patient per-
formed the entire battery on two occasions during the
screening period. It was then re-administered at baseline
(week 0), week 4 and at week 8, and again at the week 12
follow-up, 4 weeks after end of treatment.
Adverse Events (AEs) were by spontaneous report. Stand-
ard safety parameters including clinical laboratory tests of
blood and urine as well as standard safety parameters
(vital signs at each visit, ECGs, physical examination)
were completed at various time points throughout the
study. Urine was also screened at baseline, week 2, 4 and
6 for qualitative evidence of drugs of abuse.
2.3 Statistical Analysis
2.3.1 Sample Size Calculation
The sample size calculation was based on the assumption
of a 55% probability for a responder effect (at least 30%
improvement/reduction in score for primary endpoint
from baseline to week 8) for patients taking active drug,
and a 25% probability for effect in placebo, under a 1%
significance level and 80% power. The use of a 30% reduc-
tion in ADHD symptoms is more conservative than recent
trials (25% reduction; [26]) and commensurate with pre-
vious work [17,28,29]. This led to a total of 100 patients
(50 in each group), but a total of 126 subjects were ran-
domised to allow for an estimated dropout rate of 20%.
The placebo estimate for responding in the ITT popula-
tion was estimated to be 26.7%, so the placebo assump-
tion of 25%, and hence the above sample size calculation,
was justifiable.
2.3.2 Analysis of Clinical Scales
The analysis was based on a repeated measures ANOVA
model taking account intrasubject correlation of scores
over the 6 study visits. The best choice of model was a lin-
ear spatial correlation assumption.
For the systematic variation, the covariates Visit, Treat-
ment and investigator Site, were included as categorical
variables with the possibility of mutual second order
interaction. The baseline variables Sex (F, M), history of
Alcohol (Y, N), Smoker (Y, N, former), Age and Weight
were included. Any interactions with these baseline varia-
bles were not considered.
In addition, patients were grouped as Inattentive or Com-
bined according to DSM-IV [26] and it was investigated
whether treatment interacted with these categories. An
extra covariate was included in the ANOVA model to
account for an eventual third order interaction between
treatment, inattentive/combined and visit. No other
changes to the ANOVA models were made. A responder
analysis was also conducted for the investigator ratedBehavioral and Brain Functions 2008, 4:24 http://www.behavioralandbrainfunctions.com/content/4/1/24
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ADHD-RS (response was defined as ≥ 30% improvement.
The level of significance was set to 0.05, and all tests were
carried out as 2-sided.
2.3.3 Analysis of CDR data
The factor structure of the full CDR task battery has been
investigated using Principal Components Analysis [30].
This analysis confirmed the construct validity of the bat-
tery by demonstrating that the task variables within theo-
rized cognitive domains of attention, working memory
and episodic secondary memory, loaded together on five
common factors. Based on this analysis of the individual
variables, five combined scores have been derived utiliz-
ing all of the individual scores, which loaded on each fac-
tor. These combined scores have been used as outcome
measures in a variety of studies [27,30].
There are two scores for attention, Power of Attention is
the summation of the speed scores from the three atten-
tion tests (Simple and choice reaction time, digit vigi-
lance), and reflects the ability to focus attention.
Continuity of Attention combines the accuracy scores
from choice reaction time and digit vigilance, and reflects
the ability to sustain attention, Quality of working mem-
ory is a combination of the accuracy scores from the
numeric and spatial working memory tasks and reflects
the ability to hold information temporarily in memory.
Quality of episodic memory combines the accuracy scores
from the four episodic memory tasks (immediate and
delayed word recall, word and picture recognition) and
reflects the ability to store and retrieve episodic informa-
tion. Speed of Memory is the summation of the speed
scores from the two working memory tasks and the two
recognition tasks, and reflects the time taken to retrieve
information from memory.
A repeated measure ANOVA was conducted on the differ-
ence from baseline data using SAS® PROC MIXED. Fixed
terms were fitted to the model for treatment, time and
treatment*time interaction. A random effect of subjects-
within-treatment was fitted to the model. Significance of
the treatment*time interaction was tested at the 0.05 level
and all testing was two-tailed. Planned comparisons were
conducted between the two treatments at each post-dos-
ing time.
The analyses described above have been performed using
the SAS system for Windows software version 8.2 or later.
Results
3.1 Subjects
A total of 180 subjects were screened at the 3 study sites.
Of the 54 patients not randomized 32 did not meet the
study inclusion/exclusion criteria, 14 withdrew their con-
sent to participate in the study and 8 were excluded for
other reasons. The 126 subjects included in the study were
randomly allocated to treatment groups such that 63
patients received NS2359 and 63 patients received the pla-
cebo treatment. All randomized subjects began the treat-
ment protocol.
A total of 31 subjects either did not complete the 8-week
treatment period or had a missing primary endpoint at
week 0 and/or week 8. Of these subjects 9 were excluded
for a protocol deviation, 3 withdrew due to an adverse
event (increased blood pressure (NS2359 treatment); diz-
ziness, irritability and palpitations (NS2359 treatment);
dizziness and disorientation (placebo)), 13 decided not
to continue and 6 had other reasons for discontinuing the
study (4 lost to follow up; 2 in placebo group reported
lack of efficacy). A total of 51 and 44 subjects receiving
NS2359 and placebo, respectively, were defined as com-
pleting the study (Figure 1).
3.2 Demographics
Demographic data and baseline values were comparable
(not statistically different) between the NS2359 and pla-
cebo groups. Data are summarized in Table 1.
3.3 Efficacy
Investigator-rated ADHD-RS
Overall, there was no significant difference between
NS2359 and placebo in the reduction of the primary effi-
cacy variable, the investigator rated ADHD-RS total sum
of scores (7.8 (SE 1.3) and 6.4 (SE 1.3), respectively; p <
0.45). Overall, there was no significant difference in the
proportion of patients that reduced their ADHD RS score
by 30% or more between the NS2359 (33%) and placebo
(27%) groups (p = 0.55). In the inattentive subgroup,
there was a significantly larger proportion of responders
in the NS2359 treatment compared to the placebo treat-
ment (41% and 7%; p < 0.01), although there was no dif-
ferences in the combined only subgroup (30% and 42%;
p = 0.23) Figure 2.
Patient self-report ADHD-RS
In the patient-rated ADHD-RS a trend to significance was
found between NS2359 and placebo groups (7.2 (SE1.6)
and 3.2 (SE 1.2); p = 0.052). While in the inattentive sub-
group a significantly greater improvement in ADHD score
compared to those on the placebo treatment was observed
(8.1 (SE 3.1) and 0.3 (SE1.7); p < 0.05), no significant dif-
ference between the 2 groups were observed in the com-
bined group (6.9 (SE 1.8) and 6.3 (SE 1.7); p = 0.82).
The Conners (CAARS)
There was no significant difference on The Conners
(CAARS) Adult ADHD Scale between medication and pla-
cebo groups in the total sum of scores (6.4 (SE 1.5) and
4.7 (SE 1.5); p = 0.42) For the inattentive subgroup thereBehavioral and Brain Functions 2008, 4:24 http://www.behavioralandbrainfunctions.com/content/4/1/24
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was a significant reduction in score for the NS2359 treat-
ment compared to placebo (7.0 (SE 1.9) and 2.0 (SE 1.5);
p < 0.05) that was not observed for the combined sub-
group (6.3 (SE 1.9) and 6.9 (SE 2.2); p = 0.86).
The Brown Adult Scale (BROWN-AS)
There was no significant difference in The Brown Adult
Scale (10.6 (SE 2.8) and 10.8 (SE 2.8); p = 0.97) between
the two groups. For the inattentive subgroup there was a
significant reduction in score for the NS2359 treatment
compared to placebo (15.8 (SE 4.1) and 2.5 (SE 3.1); p <
0.01) that was not observed for the combined subgroup
(10.8 (SE 3.6) and 19.8 (SE 4.3); P = 0.11).
The Clinical Global Impression (CGI)
There were no significant differences in the CGI-Severity
between the NS2359 and placebo groups at any time
point (week 8, 3.9 (SD 1.1) and 4.0 (SD 1.1); p = 0.94).
However, for the inattentive subgroup treatment with
NS2359 gave a significant reduction in the mean severity
of illness compared to the placebo treatment at the end of
treatment (week 8, 3.3 (SD 0.9) and 4.2 (SD 0.8); p <
0.01) that was not found in the combined subgroup
(week 8, 4.0 (SD 1.1) and 3.8 (SD 1.3); p = 0.63).
For the CGI-Improvement assessments there were no sig-
nificant differences between the NS2359 and placebo
groups at any time point (week 8, 3.2 (SD 1.0) and 3.4
(SD 1.1); p = 0.10). However, for the inattentive subgroup
significantly greater response was reported on NS2359
compared to the placebo treatment at end point (week 8;
3.0 (SD 1.1) and 3.8 (SD 0.9); p < 0.05) that was again not
seen for the combined subgroup at any time point (week
8, 3.2 (SD1.0) and 3.0 (SD 1.2); p = 0.27).
The Hamilton Depression and Anxiety Scale
There were no significant changes in depression score in
either group over the 8-week study period, although the
difference in mean change score was significantly smaller
in the placebo group compared with the NS2359 group
Disposition of Subjects Figure 1
Disposition of Subjects.Behavioral and Brain Functions 2008, 4:24 http://www.behavioralandbrainfunctions.com/content/4/1/24
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(Mean HAM-D 3.7(SE 0.4) versus 4.6 (SE 0.4); p = 0.04).
Similarly, there were no significant differences in anxiety
score between groups over the 8-week study period
(Mean-A. 5.7 (SE 0.5) versus 6.3 (SE 0.5); p = 0.12).
Computerized Cognitive Assessments
Significant main effects of treatment were found for
Power of Attention (p < 0.015) and Quality of Episodic
Secondary Memory (p < 0.01). Figures 3 and 4 illustrate
that NS2359 improved performance during the dosing
period, and that these effects were sustained over the 4-
week washout period. Further, there was a trend for an
improvement of NS2359 over placebo for Quality of
Working Memory (p < 0.1).
3.4 Adverse Events
No serious adverse events were reported during or follow-
ing the study. There were no clinically significant changes
in the measured blood and urine parameters that were
evaluated to be related to the treatment. There were no
clinically significant changes in the blood pressure, pulse,
or the electrocardiogram evaluated to be related to the
treatment. The most prominent treatment related an
adverse effect reported was insomnia (Table 2). While
there were more reported cases of weight reduction asso-
ciated with study drug, there were no differences in rates
of reported appetite suppression between groups. Most of
the reported events were mild to moderate in severity.
Discussion
The results of this 8 week controlled study indicate that for
both primary and secondary clinical outcomes, there were
no clinically or statistically significant effects of NS2359
in ADHD symptoms compared to placebo for the overall
study population. However, NS2359 was found to favora-
bly affect cognitive function (the ability to focus attention
and also the ability to store and retrieve episodic informa-
tion) in the overall study population. A trend for improve-
ment was also seen to working memory. These
improvements are in major domains of cognitive function
and have the potential for clinical relevance in ADHD
patients.
Although there was little improvement compared to pla-
cebo in overall summary scores of ADHD on any of the
primary or secondary outcomes, there was evidence of
improvements in the inattentive subgroup with NS2359
treatment. These were seen in the patient rated ADHD-RS,
the CAARS and the Brown adult scale as well as a greater
reduction in the CGI-Severity of illness, a greater propor-
Table 1: Demographic s and clinical characteristics of Sample
NS2359 Placebo
Subjects Randomised 63 63
Gender Male 47 (74.6%) 42 (66.7%)
Female 16 (25.4%) 21 (33.3%)
Age 18–25 13 (20.6%) 13 (20.6%)
Median (Range) 35.0 (18.8–54.1) 35.2 (19.0–51.1)
Origin Caucasian 51 (81.0%) 54 (85.7%)
African American 4 (6.3%) 3 (4.8%)
Asian 3 (4.8%) 0 (0.0%)
Other 5 (7.9%) 6 (9.5%)
Previous Treatment for ADHD Yes 17 (27.0%) 18 (28.6%)
No 46 (73.0%) 45 (71.4%)
ADHD Subgroup Inattentive 17 (27.0%) 29 (46.0%)
Hyperactive/Impulsive 0 (0.0%) 1 (1.6%)
Combined 38 (60.3%) 32 (50.8%)
Not Classified 8 (12.7%) 1 (1.6%)
Weight (kg) Median (range) 80.3 (54.9–142.9) 78.9 (48.5–133.4)
Height (cm) Median (range) 173 (152–197) 175 (151–188)
Smoker Yes 16 (25.4%) 15 (23.8%)
Former 9 (14.3%) 17 (27.0%)
No 38 (60.3%) 31 (49.2%)
Alcohol Yes, Average 53 (84.1%) 58 (92.1%)
Consumption Yes, Excessive 0 (0.0%) 0 (0.0%)
No 10 (15.9%) 5 (7.9%)
Hamilton Depression score Median (Range) 3.0 (0.0–15.0) 4.0 (0.0–12.0)
CGI Severity of Illness 4 – Moderately 30 (47.6%) 29 (46.0%)
5 – Markedly 28 (44.4%) 31 (49.2%)
6 – Severely 4 (6.3%) 3 (4.8%)
7 – Extremely 1 (1.6%) 0 (0.0%)Behavioral and Brain Functions 2008, 4:24 http://www.behavioralandbrainfunctions.com/content/4/1/24
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tion of responders (>30% change) and a greater improve-
ment on the CGI Improvement scale.
The NS2359 compound improved all three of the
domains of cognitive function assessed with the CDR.
Power of Attention reflects the ability to focus attention
and to rapidly process information, and the positive
effects with NS2359 indicate that subjects were better able
to direct their attention to ongoing tasks and to sustain
concentration. The trend for improvement in working
memory indicated that the subjects were better able to
hold information temporarily 'on line', potentially facili-
tating the performance of everyday tasks and activities.
Finally the improvement to Quality of Episodic Secondary
Memory with the active medication indicated that sub-
jects were better able to encode, store and retrieve verbal
and pictorial information of an episodic nature.
These cognitive data derived from the CDR testing showed
that NS2359 improved attention, episodic memory, and
working memory in these adults with ADHD – areas pre-
viously identified as problematic in separate studies of
adults with ADHD [31]. Our combined findings of an
overall lack of response coupled with evidence of
improvement in the inattentive subtype and CDR suggest
an overall pro-cognitive effect of the medication in
ADHD. It may be that higher doses of NS2359 are
required to improve the more overt behavioral symptoms
Change from baseline scores for Power of Attention over  the study period (Mean +/- SEM) Figure 4
Change from baseline scores for Power of Attention 
over the study period (Mean +/- SEM). Improvements 
from baseline are plotted to ascend.
Mean Investigator rated ADHD-RS Score (ITT Population) for (a) all Subjects, (b) the ADHD Inattentive Subgroup and (c) the  ADHD Combined Subgroup Figure 2
Mean Investigator rated ADHD-RS Score (ITT Population) for (a) all Subjects, (b) the ADHD Inattentive Subgroup 
and (c) the ADHD Combined Subgroup. Active treatment is given week 0 to 8, where week twelve is a follow-up visit.
Change from baseline scores for Quality of Episodic Second- ary Memory over the study period (Mean +/- SEM) Figure 3
Change from baseline scores for Quality of Episodic 
Secondary Memory over the study period (Mean +/- 
SEM). Improvements from baseline are plotted to ascend.Behavioral and Brain Functions 2008, 4:24 http://www.behavioralandbrainfunctions.com/content/4/1/24
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of the ADHD. In support of the latter, a relationship
between doses of stimulants necessary to improve cogni-
tion (lower) relative to hyperactivity/impulsivity (higher)
has been speculated [32]. The lack of effect on the com-
bined group may indicate that NS2359 has little effect on
hyperactive/impulsive symptoms. An additional con-
founding effect could be that patients of the inattentive
subtype typically have fewer ADHD symptoms and hence
less severe ADHD and therefore benefit more by treat-
ment. Given the limited previous human exposure of
NS2359, a conservative low dose of the medication was
chosen for safety considerations that may have under
treated the entire spectrum of ADHD.
The findings of improvement in measures of cognitive
functioning (CDR) and in the inattentive subtype of
ADHD add to a growing literature on the usefulness of
mixed catecholaminergic reuptake inhibitors [33] on
ADHD. For example, studies with mixed dopaminergic
and noradrenergic reuptake inhibitors such as the tricyclic
antidepressants, bupropion, and noradrenergic reuptake
inhibitors (atomoxetine) have yielded generally positive
results, albeit with lower overall response rates and effect
sizes relative to the psychostimulants. Similarly, NS2359
has been shown to enhance the release of acetylcholine in
the frontal cortex and hippocampus, an effect that may be
relevant for attentional performance [20,21]. For exam-
ple, studies with procholinergic (nicotinic) agents have
demonstrated improvement in attentional/cognitive
functioning and symptoms in ADHD [16,17,34]. Hence,
the combined monoaminergic reuptake inhibition plus
pro-cholinergic effects of NS2359 may be related to the
aggregate evidence of improved cognitive functioning in
the current study.
There are a number of limitations in the current study.
Because of the nature of the study, a homogenous study
population was selected that may not generalize to typical
adults with ADHD. For example, subjects with significant
medical histories and psychiatric co-morbidities were
excluded. In addition, the sample size was relatively
small, limiting the power to detect differences. Further-
more, only one relatively low dose of NS2359 was studied
that mostly likely underestimated the effect of the medica-
tion.
One of the dilemmas of early phase studies is the determi-
nation of the optimal dose(s) for a disorder. The dose
evaluated for this study was selected on the basis of a
dose-escalating study using SPECT, as well as tolerability
data from pharmacokinetic studies. A dose of 0.5 mg/day
NS2359 was shown to give DA occupancy of 35%, which
is in the range of other clinically efficacious compounds
used for treatment of ADHD patients [35]. Given only one
low dose of NS2359 was tested, this dose may have been
insufficient to treat ADHD.
In the current study, there were no serious side effects or
reports of withdrawal symptomatology and no clinically
meaningful cardiovascular or other laboratory abnormal-
ities were detected. However the ability to detect infre-
quent and idiosyncratic reactions is limited by the small
Table 2: The Number and Severity of Adverse Events Experienced by the Subjects during the Study (only those events with ≥ 5% 
frequency are shown).
NS2359 Placebo
Body System Symptom Mild Mod Severe Mild Mod Severe
Gastrointestinal Disorders Diarrhea NOS 4 1 0 0 0 0
Dry Mouth 5 3 0 7 0 0
Dyspepsia 6 0 0 3 1 0
Nausea 4 1 0 6 0 1
General disorders and administration site conditions Fatigue 1 2 0 7 0 0
Infections & Infestations Nasopharyngitis 3 1 0 4 0 1
Upper Respiratory Tract infection 6 1 0 5 2 0
Investigations Weight decrease 5 1 0 0 0 0
Metabolism and nutrition disorders Appetite decreased NOS 5 1 0 6 0 0
Musculoskeletal and Connective Tissue Disorders Back Pain 1 1 0 5 1 0
Nervous system Disorders Dizziness 5 2 0 3 0 0
Headache NOS 15 6 1 15 5 1
Irregular Sleep Phases 3 0 1 2 0 0
Somnolence 0 0 0 4 1 0
Psychiatric disorders Initial Insomnia 1 3 0 2 0 0
Insomnia 8 3 1 2 0 1
Irritability 5 1 0 0 2 0
Middle Insomnia 7 0 0 1 0 0Behavioral and Brain Functions 2008, 4:24 http://www.behavioralandbrainfunctions.com/content/4/1/24
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number of subjects and the relatively low dose and short
duration of study treatment.
Conclusion
Despite the limitations presented above, these data show
that the current dose of NS2359 is well tolerated but insuf-
ficient to treat ADHD adequately in the general popula-
tion of adults with ADHD. A signal emerged in the
inattentive subtype and on specific measures of neuropsy-
chological functioning suggesting the potential utility of
the agent. Given the mixed findings in this group of sub-
jects, larger, parallel design dose ranging studies with
NS2359 using higher doses are warranted.
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